GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ustekinumab   Click here for help

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
Approved drug Immunopharmacology Ligand
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
ustekinumab-auub; ABP 654Wezlana; WezenlaAmgenApproved (2023 FDA, 2024 EMA)As per reference agent; Interchangeable with reference agent
ustekinumab-aekn; AVT04Selarsdi; UzpruvoAlvotech/Teva Pharmaceuticals/STADA ArzneimittelApproved (2024 FDA & EMA)As per reference agent
ustekinumab-ttwe; SB17Pyzchiva; Epyztek; EksunbiSandoz/Samsung BioepisApproved (2024 FDA, EMA and S Korea MFDS)As per reference agent; Interchangeable with reference agent*
ustekinumab; CT-P43SteQeymaCelltrionApproved (2024 EMA)As per reference agent
ustekinumab-aauz; FYB202Otulfi; Fymskina Fresenius Kabi/Formycon Approved (2024 EMA & FDA)As per reference agent; available as subcutaneous and intravenous formulations
ustekinumab-srlf; DMB-3115Imuldosa/AbsimkyAccord BioPharma/Intas PharmaceuticalsApproved (2024 EMA & FDA)As per reference agent
ustekinumab-kfce; Bmab1200Yesintek Biocon BiologicsApproved (2024 FDA, 2025 EMA)As per reference agent
ustekinumab-hmny; BAT2206StarjemzaBio-Thera Solutions/Hikma PharmaceuticalsApproved (2025 FDA)As per reference agent

*After expiry of the period of exclusivity for the first interchangeable biosimilar product.
Bioactivity Comments
The patent covering the production and use of ustekinumab (US6902734 [1]) does not provide affinity values for specific antibody clones, therefore we have included the stated range of affinities determined in the production and testing process in the interaction table below..
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-12B Primary target of this compound Hs Antibody Binding >9.6 – 11.1 pKd - 1,3
⤷ pKd >11.1 (Kd <7x10-12 M) [1]
pKd 9.6 (Kd 2.32x10-10 M) [3]